Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staphylococcus Aureus Network Adaptive Platform Trial
NCT05137119Phase 4Recruiting
- Sponsor
- University of Melbourne
- Start
- Feb 2022
- Primary completion
- Dec 2028
- Modality
- Reversible Covalent Inhibitors
- Countries
- 13
01
Overview
A Phase 4 trial of cefazolin, benzylpenicillin, clindamycin in Staphylococcus aureus bacteremia (SAB), sponsored by University of Melbourne. Started Feb 2022; status: recruiting.
02
Drugs
cefazolinbenzylpenicillinclindamycin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT05137119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137119.